Non Small Cell Lung Cancer Patients Treated With Erlotinib Six Months or Longer
Study Details
Study Description
Brief Summary
With roughly 80% of cancer patients receiving their oncology care in the community setting, the investigators are proposing to sample from a community-based center to evaluate the percentage of epidermal growth factor receptor (EGFR)-wild type patients that gain benefit from erlotinib and assess the clinical characteristics that are associated with erlotinib-responders. Additionally, biopsy specimens from enrolled patient cases that are EGFR-wt will be evaluated via exploratory genetic analysis for correlated markers.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
|
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Cohort A EGFR Wild Type patients |
|
| Cohort B EGFR mutation patients |
Outcome Measures
Primary Outcome Measures
- demographics [24 months]
To describe patient demographic characteristics of patients with erlotinib (single-agent) treatment duration of six months or longer, including patients who are EGFR-wt. Demographic characteristics include age, race,ethnicity, date of initial diagnosis, age at initial diagnosis, location of biopsy at diagnosis, extent of disease with description and location of metastatic sites, histology,and smoking history.
- treatment characteristics [24 months]
To describe patient treatment and characteristics of patients with erlotinib (single-agent) treatment duration of six months or longer, including patients who are EGFR-wt. Including number and kind of prior therapies, disease stage at initial diagnosis, sites of metastasis at time of erlotinib treatment, prior surgery, and radiation.
- outcome characteristics [24 months]
To describe patient outcome characteristics of patients with erlotinib (single-agent) treatment duration of six months or longer, including patients who are EGFR-wt including the reason for discontinuing erlotinib treatment, best response to erlotinib treatment and did patient receive any dose modifications while receiving erlotinib treatment.
Secondary Outcome Measures
- Biomarker characteristics [24 months]
To explore biomarker (BM) characteristics of EGFR-wt erlotinib responders.
- Exploratory genetic analysis [24 months]
Biopsy specimens from enrolled patient cases who are EGFR-wt will be evaluated via exploratory genetic analysis for correlated biomarkers.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Patients must have had NSCLC.
-
Patients must have received erlotinib (single-agent) for six months or longer for NSCLC in the second/third line setting or as maintenance therapy.
-
Patients must have tissue available for EGFR-mutation status testing (if not previously performed) or EGFR-mutation status test results available.
-
Patients must have tissue available for exploratory genetic analysis.
-
Patients must have all clinical information, treatment response data and outcomes data available for review.
-
Patients must be deceased.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Tennessee Oncology, PLLC | Nashville | Tennessee | United States | 37023 |
Sponsors and Collaborators
- SCRI Development Innovations, LLC
- Genentech, Inc.
Investigators
- Study Chair: David R Spigel, MD, SCRI Development Innovations, LLC
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- SCRI OUTCOMES 13